Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (230)	2/26/2002 9:27:41 AM
From: aknahow	Read Replies (1) \| Respond to of 625

MorpoSys does not have a "sole" license to the Xoma technology. It is the first phage library company to obtain the rights to use the full Xoma technology including "blocking" phage patents. Since it is the first and at this point in time the only other company to have have a license for this full technology it is being called Sole Licensee. Seems like a poor use of words to me. Apparently Xoma chose the words to put collaborators and other phage library companies on notice about possible risk of using phage technology from companies that have not perfected their own license agreements with XOMA? "The agreements also provide for a release of MorphoSys and its collaborators from any past activities using MorphoSys technology to the extent they also used XOMA's antibody expression technology, and allows MorphoSys to use the XOMA technology in combination with its own technology in any future collaborations."